Amylin Pharmaceuticals, Inc.

Wells Fargo Van Kasper Growth Stock Conference
The Wyndham Emerald Plaza
San Diego, California

Presentation by:
Daniel M. Bradbury
Executive Vice President

June 18, 2001 - 9:30 a.m.


Click here to start


Table of Contents

Amylin Pharmaceuticals, Inc.

Safe Harbor Statement

Amylin Pharmaceuticals, Inc.

Current Pipeline Status

Diabetes: Worldwide Estimates and Projections

Diabetes: A Serious, Progressive Disease

Diabetes: Devastateing Clinical and Economic Consequences

Diabetes: Inadequately Treated and Growing Rapidly

Lessons from Landmark Diabetes Studies: Intervention Works

Lessons from Landmark Diabetes Studies: Intervention Works, But at a Price #1

Lessons from Landmark Diabetes Studies: Intervention Works, But at a Price #2

SYMLIN™ (pramlintide acetate) Overview

SYMLIN Patient Focus People With Diabetes Who Use Insulin

SYMLIN™ (pramlintide acetate) Glucose and Weight Effect at One Year

SYMLIN Market Opportunity North America and Western Europe

SYMLIN Market Opportunity United States

SYMLIN Market Opportunity: US Insulin Prescriptions Highly Concentrated

SYMLIN Commercial Operations Sales Planning Model

SYMLIN Commercial Operations Experienced Core Commercial Team

Amylin the Hormone Medical Education Program

Upcoming Medical Meetings

AC2993 (synthetic exendin-4) Overview

AC2993 (synthetic exendin-4) Patient Focus

AC2993 (synthetic exendin-4)

AC2993 (synthetic exendin-4)

AC2993 LAR

Potential Diabetes Target Markets

AC3056

Expanding the Pipeline

Financial Overview

Goals for 2001